LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Marzo 2024 - 11:01PM
Business Wire
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”) today
announced that a majority of the independent members of LENSAR’s
board of directors granted seven newly-hired non-executive
employees stock options to purchase an aggregate of 4,175 shares of
the Company’s common stock. The options were granted as of March 1,
2024, as inducements material to each employee entering into
employment with the Company. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $4.70 per share, which is
equal to the closing price of the Company’s common stock on the
grant date. The options vest as to 25% of the total amount of the
award on the one-year anniversary of the grant date and in
thirty-six substantially equal monthly installments thereafter,
subject to the new employee’s continued service with the company.
Each stock option has a 10-year term. The options are subject to
the terms and conditions of LENSAR’s 2024 Employment Inducement
Incentive Award Plan and a stock option agreement covering the
grant.
About LENSAR
LENSAR is a commercial-stage medical device company focused on
designing, developing, and marketing advanced systems for the
treatment of cataracts and the management of visually significant
astigmatism as an integral aspect of the cataract procedure. LENSAR
has developed its next-generation ALLY® Adaptive Cataract Treatment
System, the first platform to integrate proprietary imaging and
software, with an extremely fast dual-pulse femtosecond laser in a
compact, highly ergonomic system. ALLY is designed to transform
cataract surgery by utilizing LENSAR’s advanced technologies with
the ability to perform the entire procedure in an operating room or
in-office surgical suite, delivering operational efficiencies and
reduced overhead. ALLY includes LENSAR’s proprietary Streamline®
software technology, designed to guide surgeons to achieve better
outcomes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240301026377/en/
Thomas R. Staab, II, CFO ir.contact@lensar.com
Lee Roth / Cameron Radinovic Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com
Grafico Azioni LENSAR (NASDAQ:LNSR)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni LENSAR (NASDAQ:LNSR)
Storico
Da Gen 2024 a Gen 2025